6 assets in Poorly Differentiated Thyroid Gland Carcinoma

Therapeutic assets addressing Poorly Differentiated Thyroid Gland Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Poorly Differentiated Thyroid Gland Carcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
Fludarabine Poorly Differentiated Thyroid Gland Carcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
Ipilimumab Poorly Differentiated Thyroid Gland Carcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
Lifileucel Poorly Differentiated Thyroid Gland Carcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
Nivolumab Poorly Differentiated Thyroid Gland Carcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
[177lu]lu-akir001 Poorly Differentiated Thyroid Gland Carcinoma	Karolinska University Hospital	Early P1	C (39)